70 citations
,
February 2018 in “Seminars in Arthritis and Rheumatism” This study found that belimumab helped achieve low disease activity in over 40% of systemic lupus erythematosus patients in real-life settings, alongside reduced corticosteroid use and fewer flares.
This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.
November 2025 in “Reumatismo” In this study, the choice between Belimumab and Anifrolumab for treating Systemic Lupus Erythematosus was mainly influenced by the clinical features of the disease, such as chronic-active or relapsing-remitting courses and specific manifestations like cutaneous involvement or arthritis.
November 2025 in “DOAJ (DOAJ: Directory of Open Access Journals)” This study observed that the choice between using Belimumab and Anifrolumab for treating active Systemic Lupus Erythematosus was mainly based on clinical phenotype, with Anifrolumab linked to chronic-active disease and Belimumab associated with relapsing-remitting disease.
October 2024 in “American Journal of Case Reports” This case report describes a 54-year-old Saudi woman with systemic lupus erythematosus and severe alopecia, where conventional treatments were ineffective. When belimumab was ineffective, baricitinib led to significant improvement in her condition, suggesting further research is needed to evaluate baricitinib's role in managing SLE.